教育经历 1986.8-1991.7 青岛大学医学院, 本科 1992.8-1995.7 东南大学医学院 微生物免疫学硕士研究生 工作经历 1991.8-1992.8 山东省章丘人民医院内科, 住院医师 1995.8-2002.10 南京市第一医院中心实验室, 主管技师 2002.11-2003.12 , 北卡罗来纳大学病理系, 访问学者 2004.1-2004.12 北卡罗来纳大学细胞与生物学系 博士后 2005.1-2016.12 北卡罗来纳大学基因治疗中心, 副研究员 2017- 北卡罗来纳大学药学院, 助理教授 2018.07— 华东理工大学药学院 教授，博士生导师

Sun J, Livingston EW, Broberg ML, Johansen PB, Ley CD, Knudsen T, Ezban M, Bateman T, Monahan PE, Taves S. Prophylactic administration of glycoPEGylated factor IX provides protection and joint outcome superior to recombinant factor IX after induced joint bleeding. J Thromb Haemost. 2019 May 31. doi: 10.1111/jth.14527.

Zhong C, Szollosi D, Sun J, Hua B, Ghoneim O, Bill A, Zhuang Y, Edafiogho I. Novel Piperazino-Enaminones Decrease Pro-inflammatory Cytokines Following Hemarthrosis in a Hemophilia Mouse Model. Inflammation. 2019. 5 doi: 10.1007/s10753-019-01032-y. * 通讯作者, 华东理工大学为第一研究单位

He P, Zhang F, Zhong C, Li M, Zheng J, Hua B, Sun J*. Timely and large dose of clotting factor IX provides better joint wound healing after hemarthrosis in hemophilia B mice. Int J Hematology. 2019 110(1):59-68 * 通讯作者, 华东理工大学为第一研究单位

Junjiang Sun, Shao W, Chen X, Merricks EP, Wimsey L, Abajas YL, Niemeyer GP,Lothrop CD, Monahan PE, Samulski RJ, Nichols TC, Li C. An observational study from long-term AAV re-administration in two hemophilia dogs. Molecular Therapy - Methods & Clinical Development 2018, 10:257-267

Junjiang Sun, Yuan Z, Abajas YL, Szollosi DE, Hu G, Hua B, Xiao X, Li C. A retrospective study of cytokine profiles changes in mice with FVIII inhibitor development after AAV mediated gene therapy in hemophilia A mouse model. Human Gene Therapy 2018， 29(3):381-389

Chai Z, Junjiang Sun, Rigsbee KM, Wang M, Jude Samulski R, Li C. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion. J Control Release. 2017 262:348-356

Junjiang Sun, Baolai Hua, Xiaojing Chen, Richard J Samulski and Chengwen Li. Gene Delivery of activated Factor VII using Alternative AAV serotype Improves Hemostasis in hemophiliac Mice with FVIII Inhibitors and AAV neutralizing antibodies. Hum Gene Ther. 2017, 28(8):654-666

Junjiang Sun, Baolai Hua, Eric W. Livingston, Sarah Taves, Peter B. Johansen, Maureane Hoffman, Mirella Ezban, Dougald M. Monroe, Ted A. Bateman, and Paul Edward Monahan. Abnormal time course of joint and bone healing in hemophilia B mice is improved by extending factor IX activity after hemarthrosis. Blood 2017,129(15):2161-2171

Wang M, Junjiang Sun, Crosby A, Woodard K, Hirsch ML, Samulski RJ, Li C. Direct interaction of human serum proteins with AAV virions to enhance AAV transduction: Immediate impact on clinical applications. Gene Ther. 2017,24(1):49-59

Monahan PE, Junjiang Sun, Gui T, Hu G, Hannah WB, Wichlan DG, Wu Z, Grieger JC, Li C, Suwanmanee T, Stafford DW, Booth CJ, Samulski JJ, Kafri T, McPhee SW, Samulski RJ. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther. 2015, 26(2):69-81

Lau AG, Sun J, Hannah WB, Livingston EW, Heymann D, Bateman TA, Monahan PE. Joint bleeding in factor VIII deficient mice causes an acute loss of trabecular bone and calcification of joint soft tissues which is prevented with aggressive factor replacement. Haemophilia. 2014, 20(5):716-22.

Narkbunnam N, Junjiang Sun, Hu G, Lin FC, Bateman TA, Mihara M, Monahan PE. IL-6 Receptor Antagonist as Adjunctive Therapy with Clotting Factor Replacement to Protect Against Bleeding-Induced Arthropathy in Hemophilia. J Thromb Haemost, 2013, 11(5): 881-93

Paul E. Monahan*, Clinton D. Lothrop*, Junjiang Sun*, Matthew L. Hirsch, Tal Kafri, Boris Kantor1, Rita Sarkar, D. Michael Tillson, Joseph R. Elia, R. Jude Samulski. Canine hemophilia A corrected via combination therapy with large transgene AAV and FDA approved drug: A strategy for broad clinical application. Molecular Therapy, 2010, 18(11):1907-16 (* Equally contributed )

Shen S, Bryant KD, Junjiang Sun, Brown SM, Troupes A, Pulicherla N, Asokan A. Glycan binding avidity determines the systemic fate of adeno-associated virus type 9. J Virol, 2012,86(19):10408-17

Rehman H, Junjiang Sun*, Shi Y, Ramshesh VK, Liu Q, Currin RT, Lemasters JJ, Zhong Z. NIM811 Prevents Mitochondrial Dysfunction, Attenuates Liver Injury, and Stimulates Liver Regeneration After Massive Hepatectomy. Transplantation, 2011, 91(4):406-12 (* Equally contributed)

Chen S, Sanford CA, Junjiang Sun, Choi V, T Van Dyke T, Samulski RJ and Rathmell WK. VHL and PTEN loss coordinate to promote mouse liver vascular lesions. Angiogenesis, 2010, 13(1): 59-69

Monahan PE and Junjiang Sun. Hemophilic Synovitis: Factor VII and the Potential Role of Extravascular Factor VIIa. Thrombosis Research 2010, 125S1: S63-66

Li C, Goudy K , Hirsch M , Asokan A, Fan Y, Alexander J, Junjiang Sun , Monahan PE , David Seiber, Sidney J, Sette A , Tisch R, Frelinger J, Samulski RJ. Cellular Immune Response to Cryptic Epitopes During Therapeutic Gene Transfer. PNAS, 2009, 106(26):10770-4

Wu Z, Junjiang Sun, Zhang T, Yin C, Yin F, Van Dyke T, Samulski RJ, Monahan PE. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Molecular Therapy 2008,16(2):280-9

Junjiang Sun, Hakobyan N, Valentino LA, Feldman BL, Samulski RJ, Monahan PE. Intra-articular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX. Blood, 2008,112(12):4532-41